Benzoazepine derivative as potent antagonists of the glycine binding site associated to the NMDA receptor

Farmaco

Volumn 58, Issue 9, 2003, Pages 723-738

  Di Fabio, Romano ^a   Micheli, Fabrizio ^a   Baraldi, Davide ^a   Bertani, Barbara ^a   Conti, Nadia ^a   Dal Forno, Giovanna ^a   Feriani, Aldo ^a   Donati, Daniele ^a   Marchioro, Carla ^a   Messeri, Tommaso ^a   Missio, Andrea ^a   Pasquarello, Alessandra ^a   Pentassuglia, Giorgio ^a   Pizzi, Domenica A ^a   Provera, Stefano ^a   Quaglia, Anna M ^a   Sabbatini, Fabio M ^a  

^a GSK   (Italy)

Author keywords

Benzoazepine derivatives; Glycine; NMDA receptor

Indexed keywords

8 CHLORO 2 OXO 5 PHENYLCARBAMOYLMETHYLENE 1,2,3,4 TETRAHYDRO 1H BENZ[B]AZEPINE 3 CARBOXYLIC ACID; 8 CHLORO 2 OXO 5 PHENYLCARBAMOYLMETHYLENE 2,3,4,5 TETRAHYDRO 1H BENZ[B]AZEPINE 3 CARBOXYLIC ACID AMIDE; 8 CHLORO 2 OXO 5 PHENYLCARBAMOYLMETHYLENE 2,3,4,5 TETRAHYDRO 1H BENZ[B]AZEPINE 3 CARBOXYLIC ACID HYDROXAMIDE; 8 CHLORO 2 OXO 5 PHENYLCARBAMOYLMETHYLENE 2,3,4,5 TETRAHYDRO 1H BENZ[B]AZEPINE 3 CARBOXYLIC ACID PHENYLAMIDE; AZEPINE DERIVATIVE; GLYCINE; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; CONTROLLED STUDY; CONVULSION; DRUG POTENCY; DRUG SYNTHESIS; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NEUROPROTECTION; NONHUMAN; STATISTICAL SIGNIFICANCE; STRUCTURE ACTIVITY RELATION;

EID: 0141453186     PISSN: 0014827X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-827X(03)00166-6     Document Type: Article

References (31)

1. Choi D.W., Rothman S.M. The role of glutamate neurotoxicity in hypoxic-ischemic neuronal death. Annu. Rev. Neurosci. 13:1990;171-182.
2. Graham S.H., Chen J., Sharp F.R., Simon P.R. Limiting ischemic injury by inhibition of excitatory amino acid release. J. Cerebr. Blood Flow Metab. 13:1993;88-97.
3. McCullogh J. Excitatory amino acid antagonists and their potential for the treatment of ischemic brain damage in man. Br. J. Clin. Pharmacol. 34:1992;106-114.
4. Choi D.W. Methods for antagonizing glutamate neurotoxicity. Cerebrov. Brain Metab. Rev. 2:1990;105-147.
5. Meldrum B., Garthwaite J. Excitatory amino acid neurotoxicity and neurodegenerative disease. Trends Pharm. Sci. 11:1990;379-387.
6. Choi D.W. Cerebral hypoxia: some new approaches and unanswered questions. J. Neurosci. 10:1990;2493-2501.
7. Meldrum B. Protection against ischemic neuronal damage by drugs acting on excitatory neurotransmitters. Cerebrovasc. Brain Metab. Rev. 2:1990;27-57.
8. Zivin J.A. Neuroprotective therapies in stroke. Drugs. 3:1997;83-88.
9. Collingridge G.L., Watkins J.C. The NMDA Receptor. 2nd ed. 1994;IRL Press, Oxford (England).
10. Johnson J.W., Asher P. Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature. 325:1987;529-531.
11. Kleckner N.W., Dingledine R. Requirement for glycine in activation of NMDA-receptors expressed in Xenopus oocytes. Science. 241:1988;835-837.
12. Kemp J.A., Leeson P.D. The glycine site of the NMDA receptor-five years on. Trends Pharmacological Sci. 14:1993;20-25.
13. Leeson P.D., Iversen L.L. The glycine site on the NMDA receptor: structure-activity relationships and therapeutic potential. J. Med. Chem. 37:1994;4053-4067.
14. Iversen L.L., Kemp J.A. Collingridge G.L., Watkins J.C. The NMDA Receptor. 2nd ed. 1994;469-486 IRL Press, Oxford (England). Chapter 20.
15. Di Fabio R., Gaviraghi G., Reggiani A. Strychnine-insensitive glycine binding site and the NMDA receptor. La Chimica e l'Industria. 78:1996;283-289.
16. Tranquillini M.E., Reggiani A. Glycine-site antagonists and stroke. Exp. Opin. Invest. Drugs. 8:1999;1837-1848.
17. Micheli F., Pasquarello A. Glycine antagonists for the treatment of stroke: a literature survey (1997-1999). Investigational Drugs. 3:2000;318-328.
18. Donati D., Micheli F. Recent developmentes in glycine antagonists. Exp. Opin. Ther. Patents. 10:2000;667-673.
19. Antolini M., Donati D., Micheli F. Recent developmentes in glycine antagonists. Curr. Opin. Investigational Drugs. 1:2000;230-235.
20. Di Fabio R., Capelli A.M., Conti N., Cugola A., Donati D., Feriani A., Gastaldi P., Gaviraghi G., Hewkin C.T., Micheli F., Missio A., Mugnaini M., Pecunioso A., Quaglia A.M., Ratti E., Rossi L., Tedesco G., Trist D.G., Reggiani A. Substituted indole-2-carboxylates as in vivo potent antagonists acting at the strychnine-insensitive glycine binding site. J. Med. Chem. 40:1997;841-850.
21. Di Fabio R., Cugola A., Donati D., Feriani A., Gaviraghi G., Ratti E., Trist D.G., Reggiani A. Identification and pharmacological characterization of GV150526, a novel glycine antagonist as a potent neuroprotective agent. Drugs Future. 23:1998;61-69.
22. Hewkin C.T., Di Fabio R., Conti N., Cugola A., Gastaldi P., Micheli F., Quaglia A.M. New synthesis of substituted 2-carboxyindole derivatives. Versatile introduction of a carbamoylethynyl moiety at the C(3) position. Arch. Pharm. Pharm. Med. Chem. 332:1999;55-58.
23. Micheli F., Di Fabio R., Capelli A.M., Cugola A., Cucuruto O., Feriani A., Gastaldi P., Gaviraghi G., Marchioro C., Orlandi A., Pozzan A., Quaglia A.M., Reggiani A., van Amsterdam F. Cycloalkyl indol-2-carboxylates as useful tools for mapping the 'north-eastern' region of the glycine binding site associated with the NMDA receptor. Arch. Pharm. Pharm. Med. Chem. 332:1999;73-80.
24. Giacobbe S.A., Di Fabio R., Baraldi D., Cugola A., Donati D. Synthesis of substituted indole-2-carboxylates: versatile introduction of a carbamoyl moiety at the C-3 position. Synth. Commun. 29:1999;3125-3135.
25. Di Fabio R., Conti N., DeMagistris E., Feriani A., Provera S., Sabbatini F.M., Reggiani A., Rovatti L., Barnaby R.J. Substituted analogues of GV150526 as potent glycine binding site antagonists in animal models of cerebral ischemia. J. Med. Chem. 42:1999;3486-3493.
26. Donati D., Di Fabio R. Synthesis and pharmacological properties of novel glycine antagonists. Pharmaceutica Acta Helvetiae. 74:2000;239-245.
27. It is worth noting that, when the Wittig reaction was attempted in the presence of a base such as DBU, the competitive elimination reaction of the protected secondary alcohol was observed.
28. Levin J.I., Turos E., Weinreb S.M. An alternative procedure for the aluminum-mediated conversion of esters to amides. Synth. Commun. 12:1982;989-993.
29. 2+ generated from the catalytic cycle, followed by elimination of PdH species.
30. The introduction of the tert-butyl ester protecting group was necessary in order to avoid the exo/endo isomerization of the double bond in the benzoazepine derivative observed in the final deprotection step under basic conditions.
31. The research complied with national legislation and with company policy on the Care and Use of Animals and with related codes of practice.